Quick Answer
MindMaze Therapeutics Holding SA reported Research And Development Expense of $1.33 million for the year ending 2023.
- MindMaze Therapeutics Holding SA showed a decrease of -89.3% in Research And Development Expense from 2022 to 2023.
- This data is from MindMaze Therapeutics Holding SA's annual report (Form 10-K), filed with the SEC on April 30, 2024.
- XBRL data for this metric is available from 2021 to 2023 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 3 years of available data (2021 to 2023), MindMaze Therapeutics Holding SA's Research And Development Expense has declined by 93.0%.
- Historical annual values: Fiscal year 2023: $1.33 million | Fiscal year 2022: $12.39 million | Fiscal year 2021: $19.02 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: